Animal Vaccines Market - By Animal Type, By Vaccine Type, By Application, By Route of Administration, By Distribution Channel - Global Forecast 2025 - 2034

Animal Vaccines Market Size

The global animal vaccines market was valued at USD 9.9 billion in 2024. The market is expected to grow from USD 10.4 billion in 2025 to USD 19 billion in 2034, growing at a CAGR of 6.9% during the forecast period. The market is experiencing considerable growth driven by increasing global animal population, high adoption of pet animals for companionship, rising cases of infectious diseases in animals, and rising expenditure on veterinary care.
 

As per the 2024 Global Pet Parent Study, the global pet population at around 1 billion. Similarly, the worldwide population of livestock is also rising to meet the increasing demand for meat, milk, and eggs. For example, the global live cattle population was approximately 1.57 billion heads in 2023. Further, global poultry population reached 27.22 billion, and pig population was estimated at approximately 778 million. Such high volume of animals increases the demand for various animal healthcare products such as vaccines, thereby boosting the market growth.
 

Further, the increasing occurrence of zoonotic diseases as well as the possibility of infectious outbreaks in companion and livestock animals have been propelling the animal vaccines market. There are stricter policies pertaining to the health of animals due to concerns regarding food security globally. These policies have led to the implementation of animal vaccination programs aimed at ensuring disease control. Regulatory authorities across the world are imposing strict policies to prevent the outbreak of animal-borne diseases and propelling the use of vaccines to reduce economic damages of livestock industry, thus contributing to market growth. Further, several technological advancements in the field of veterinary medicine are set to positively influence the animal health industry.
 

Animal vaccines, also known as veterinary vaccines, are biological formulations developed to protect animals from bacterial, viral, and fungal infections caused by pathogens. Animal vaccines are considered an effective way to prevent diseases and help limit the disease burden in companion and farm animals. These vaccines play an anchoring role in improving the health and welfare of animals, promoting the production of livestock, and restricting pathogen transmission from animals to humans.
 

Animal Vaccines Market Trends

• The market has experienced immense growth with the development of recombinant DNA and mRNA vaccines owing to biotechnology innovations. These vaccines offer more advantages than traditional live or inactivated vaccines, including higher specificity, longer-lasting immunity, and reduced risk of adverse reactions. Furthermore, companies are focusing on research to develop vector and subunit vaccines, which strengthen immune responses while limiting side effects.
   
• Thus, as more of these vaccine technologies receive regulatory approval, the market will grow rapidly in the coming years.
   
• In addition, the higher occurrence of zoonotic and other infectious diseases in animals is a major factor fueling the animal vaccine market. The increased prevalence of diseases such as avian influenza, rabies, brucellosis, bovine tuberculosis, and PRRS (Porcine Reproductive and Respiratory Syndrome) severely affects animal health, livestock productivity, and public health. For example, studies report that each year, about 400 to 500 cases of rabies are reported in domestic pets like cats, dogs, and ferrets. As per the CDC, every year, rabies kills 70,000 people worldwide. Dogs cause 99% of human rabies deaths outside the U.S.
   
• The rising risk of zoonotic diseases —as witnessed in COVID-19 and monkeypox outbreaks—has shifted focus toward preventive approaches, including extensive vaccination campaigns.
   
• Furthermore, the surge in pet adoption and increased consumer spending on pet health has greatly increased the need for preventive veterinary services, especially vaccinations. Dog and cat owners are spending more on both primary and secondary vaccines such as canine distemper, rabies, feline leukemia, and Lyme disease. Moreover, veterinary clinics and pet hospitals are also promoting annual vaccination services, which further propels demand.
   
• Moreover, high adoption of pet insurance is expected to be an instrumental factor in driving the market expansion. According to the North American Pet Health Insurance Association, in 2023, the U.S. experienced 17.1% growth in total insured pets. Pet insurance coverage and increased awareness of preventable diseases will positively drive market growth.
   

Animal Vaccines Market Analysis

Based on the animal type, the market is segmented into livestock animals and companion animals. In 2024, livestock animals segment accounted for highest market share with a revenue of USD 6.4 billion. The livestock animals include poultry, cattle, swine, aquaculture, and sheep and goats.
 

• The livestock industry dominates the market because it has a major economic and industrial value in the global food economy. Livestock, including cattle, poultry, swine, and sheep, are essential for meat, dairy, and egg production, making disease prevention a critical concern for farmers and food producers.
   
• Vaccination helps contain outbreaks of infectious diseases, such as foot-and-mouth disease, avian influenza, and swine fever, that can cause economic losses. As a result, substantial private and government spending on immunization plans drives the market for livestock vaccines.
   
• Further, rising prevalence of zoonotic diseases among farm animals increases the demand for livestock animal vaccines. Several zoonotic diseases such as leptospirosis, Johne’s Diseases (JD), viral respiratory tract infections, bovine ephemeral fever, and infectious bovine rhinotracheitis (IBR), among others, affect farm animals worldwide and increase the disease burden.
   
• For instance, bovine leptospirosis often results in economic losses through its severe impact on reproduction performance and it threatens human health at human-cattle-environment interfaces. As per a study published by the National Institute of Health (NIH), the estimated average annual cost of leptospirosis due to loss of productivity was approximately USD 29.3 billion in 2019. Thus, rising prevalence of these conditions is expected to augment the demand for animal vaccines, thereby stimulating the market growth during the analysis timeframe.
   

Based on the vaccine type, the animal vaccines market is classified into attenuated live vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, recombinant vaccine, and other vaccine types. The attenuated live vaccine segment held the highest revenue in 2024 with a market share of 44.1%.
 

• This majority market share is primarily owing to high clinical efficacy as compared to inactivated vaccines.
   
• Majority of the commercially available veterinary vaccines are live attenuated vaccines. These vaccines can induce humoral as well as cell-mediated immune responses, thereby offering long-term effectivity.
   
• These vaccines are also known to induce higher immunogenicity, and often a single vaccine dose is sufficient to provide long-term protection.
   
• Live attenuated vaccines are highly preferred in emerging economies owing to high cost-effectivity as compared to other vaccines. Thus, numerous benefits mentioned above are propelling the market growth positively.
   

Based on the application, the animal vaccines market is segmented into bacterial infections, viral infections, parasitic infections, fungal infections, and other applications. The viral infections segment dominated the market in 2024 and is anticipated to reach USD 10.7 billion by 2034.
 

• The viral infections segment holds a significant share in the market due to the high prevalence of viral diseases in livestock and companion animals.
   
• Viral infections like foot and mouth disease, rabies, porcine circovirus, and infectious bovine rhinotracheitis have high economic and health burdens, which increases the demand for effective vaccines. For instance, foot and mouth disease (FMD) is a severe, highly contagious viral disease of livestock that has a significant economic impact.
   
• Additionally, the rising occurrence of zoonotic infections has increased the demand for both livestock and companion animal viral vaccines. Diseases such as rabies, leptospirosis, and certain influenza strains are dangerous to public health. Therefore, veterinary and government agencies worldwide are increasing vaccination drives to control outbreaks of these diseases.
   

Based on the route of administration, the animal vaccines market is classified into injection vaccines, oral vaccines, and immersion/spray vaccines. The injection vaccines segment dominated the market in 2024 and is anticipated to witness rapid growth at a CAGR of 6.6% over the forecast years.
 

• The injection vaccine segment dominates the animal vaccine market because of its proven efficiency and ease of administration. Injectable vaccines create a strong immune response in animals, providing long-lasting immunity.
   
• These vaccines are routinely used to prevent many infectious diseases in both livestock and pets.
   
• The widespread adoption of injectable vaccines can be attributed to their proven reliability, ease of distribution, and ability to target specific pathogens effectively.
   
• Moreover, compared to oral or other types of vaccines, injectable vaccines are more cost-effective in terms of dosages, which is an advantage in these highly competitive markets.
   

Based on the distribution channel, the animal vaccines market is bifurcated into veterinary hospital pharmacies, retail pharmacies, and E-commerce. in 2024, the veterinary hospital pharmacies segment dominated the market and is expected to grow at CAGR of 7% from 2025 to 2034.
 

• Veterinary hospital pharmacies are dedicatedly established to dispense medications for animals. A wide range of animal healthcare products, including vaccines, are available in pharmacies. As they provide a comprehensive range of medications, it makes them a convenient and reliable source for purchasing animal healthcare products.
   
• Factors such as their brand recognition, high reputation for quality products, and expertise in medication dispensing are responsible for market dominance.
   
• Additionally, these pharmacies offer professional consultations that ensure the right vaccines are administered according to animal health needs, which further boosts their market share in the market.
   

North America animal vaccines market held the largest market share of 40.6% in 2024 in the global market, and it is anticipated to expand at a 6.4% CAGR over the forecast period.
 

The U.S. market was valued at USD 3.2 billion in 2021. The market size was valued at USD 3.3 billion in 2022 and reached USD 3.5 billion in 2023.
 

• According to the American Pet Products Association (APPA) 2021 data, U.S. pet ownership has been on the rise in recent years, with 67% of households owning a pet. Similarly, Americans are increasingly willing to spend on their pets, with total pet expenditures reaching USD 103.6 billion in 2020, a 6.7% increase from the previous year, as reported by the APPA.
   
• Further, the country also boasts a high population of livestock animals. For instance, there were 87.2 million head of cattle and calves on the U.S. farms as of January 2024.
   
• Such high volume of companion and livestock animals in the country increases the demand for various animal vaccines, thus boosting the growth of the U.S. market.
   
• Further, increased government funding and support along with robust animal health policies in the U.S also assist in the high market share.
   

Europe animal vaccines market accounted for USD 2.7 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• According to the European Pet Food Industry, approximately 90 million households in the EU own a pet (~46%). The rising pet adoption in the European region, along with increasing government initiatives to improve animal healthcare, is expected to drive the market growth.
   
• Also, the presence of key market players such as Boehringer Ingelheim, Elanco, and Virbac strengthens Europe's position in the market. These companies are actively participating in innovation through the development of new vaccines, which helps in market growth.
   

Germany animal vaccines market is anticipated to witness significant growth in coming years.
 

• As of 2023, 45% of German households have a pet and 14% of households have two pets or more. This totals to approximately 34.3 million pets. Cats and dogs are the most popular house pets, with 25% of German households owning cats and 21% of households owning dogs. Moreover, in 2024, the cattle population in Germany was 10.63 million.
   
• The rising adoption of pet and livestock animals coupled with surging expenditure on veterinary care is set to augment the market size in Germany.
   
• Moreover, the rise in livestock diseases, such as African swine fever and avian influenza, has emphasized the importance of insurance coverage. In 2020, African Swine Fever (ASF) caused significant losses in Germany. Further, since December 2022, more than 120 outbreaks of avian influenza in bird populations have been documented in Germany. These disease outbreaks increase the demand for animal vaccines in the country.
   

The Asia Pacific animal vaccines market demonstrates significant growth potential.
 

• The market in the Asia Pacific region is growing rapidly due to the rise in pet ownership, advancements in animal health awareness, and the improvement of veterinary care infrastructure.
   
• Countries such as China, India, and Japan are becoming large consumers of animal vaccines because of the expanding dairy and meat industries that demand high standards of preventive veterinary care for productivity and animal welfare.
   
• Moreover, presence of both international market players and local regional manufacturers intensifies the market competition, further driving the regional market growth.
   

India animal vaccines market is poised to witness high growth over the analysis period.
 

• India has a large pet population with over 31 million pet dogs and 2.44 million pet cats. The increasing pet ownerships and rising disposable income in the country, coupled with high expenditure on pet healthcare will offer lucrative market growth opportunity in the country.
   
• In addition, rapidly expanding veterinary infrastructure in the country such as veterinary hospitals and clinics will further enhance the market growth.
   
• Furthermore, several government initiatives to support the animal health and wellness also stimulate the market growth. For instance, the National Animal Disease Control Programme is a flagship scheme launched in 2019 that aims to control foot and mouth disease and brucellosis by vaccinating the animals. Such initiatives aid in high adoption of animal vaccines, thus fostering the market growth.
   

Brazil animal vaccines market is anticipated to witness rapid growth over the forecast years.
 

• Brazil is poised to expand rapidly within the Latin America vaccines market due to its advanced livestock sector and rising animal health product consumption. Being one of the world’s leading beef, poultry, and pork producers, Brazil’s animal husbandry practices require efficient animal vaccines to safeguard the health and productivity of livestock.
   
• Further, the increasing trend of pet ownership, especially in urban areas, also fuels the need for companion animal vaccines. In 2023, Brazil counted over 160 million pets, of which more than 62 million were dogs.
   
• Additionally, the presence of several international as well as local veterinary companies in the country further aid in the market growth.
   

Saudi Arabia animal vaccines market is set for lucrative growth in the Middle East and Africa market.
 

• The increasing pet ownership in the country, rising disposable income coupled with rapidly expanding veterinary infrastructure will offer lucrative market growth opportunity in the country.
   
• In addition, rising government initiatives to boost animal welfare and support businesses in the veterinary industry aid in the market growth.
   

Animal Vaccines Market Share

The market is highly competitive, with several key companies striving to develop novel formulations in the market. Several major organizations, local small players, and start-ups are joining the industry competition. The top 6 companies in the market such as Zoetis, Elanco Animal Health, Merck Animal Health, Virbac, Vetoquinol, and Boehringer Ingelheim International account for approximately 60 – 70% of the global market share.
 

Additionally, there are several local and regional players operating in the market are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings. For instance, in February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D to prevent infectious diseases from animal origin and improve animal health. Such initiatives by market players enhances the competitive landscape in the market, thereby boosting the market growth.
 

Animal Vaccines Market Companies

Prominent players operating in the animal vaccines industry include:

• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Bioveta
• Ceva Sante Animale
• Durvet
• Dechra Pharmaceuticals
• Elanco Animal Health
• Henry Schein Animal Health (Covetrus, Inc.)
• Hipra Animal Health Limited
• Indian Immunologicals
• Merck Animal Health
• Neogen Corporation
• Vetoquinol
• Virbac
• Zoetis
   

Boehringer Ingelheim has a notable presence in the animal vaccines market. The company offers a wide range of animal healthcare products, including vaccines, anti-infectives, parasiticides, and therapeutic solutions designed to improve animal health. Its main products include vaccines for respiratory and viral diseases such as Ingelvac CircoFLEX for porcine circovirus and Pratel for canine parasites. The company is also known for its Bovilis line, which provides protection against diseases like bovine respiratory syncytial virus (BRSV) and infectious bovine rhinotracheitis (IBR), solidifying its position as a leader in veterinary immunology.
 

Zoetis is one of the leading global animal health companies. The company discovers, develops, manufactures, and commercializes a diverse portfolio of animal health medicines and vaccines and has operations in over 100 countries. The company's dedication to R&D stimulates innovation in animal healthcare, allowing the launch of novel, effective, and safe treatments.
 

Animal Vaccines Industry News:

• In February 2025, Zoetis received a conditional license from the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB), for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. This vaccine is specifically labeled for use in chickens. The conditional license was granted based on the vaccine's demonstrated safety, purity, and reasonable expectation of efficacy, as supported by serology data.
   
• In February 2025, Elanco Animal Health partnered with Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine specifically for dairy cattle in the U.S. This collaboration aims to address the cross-species transmission of HPAI, which has impacted nearly 1,000 dairy herds since March 2024.
   
• In August 2022, Zoetis expanded the poultry product portfolio with the Poulvac Procerta HVT-IBD vaccine to protect poultry against Infectious Bursal Disease (IBD). This added to the company’s line of recombinant vector vaccines.
   
• In July 2020, Merck Animal Health announced USD 100 million investment in its vaccine manufacturing site in the U.S., to scale up the vaccine production. This investment helped the company to facilitate operational expansion, further aiding in revenue generation.
   
• In April 2018, Zoetis announced the development of an animal vaccine manufacturing and research complex in China. This strategic move helped the company to accelerate research and development activities and production capabilities concerning veterinary vaccines, thereby gaining a competitive advantage.
   

The animal vaccines market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Animal Type

• Livestock animals    
  • Poultry
  • Cattle
  • Swine
  • Aquaculture
  • Sheep and goats 
• Companion animals 
  • Canine
  • Feline
  • Equine
  • Avian

Market, By Vaccine Type

• Attenuated live vaccine
• Conjugate vaccine
• Inactivated vaccine
• DNA vaccine
• Recombinant vaccine
• Other vaccine types

Market, By Application

• Bacterial infections
• Viral infections
• Parasitic infections
• Fungal infections
• Other applications

Market, By Route of Administration

• Injection vaccines
• Oral vaccines
• Immersion/spray vaccines

Market, By Distribution Channel

• Veterinary hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE